阿斯利康终止一项肺癌三期临床试验,称疗效难达主要终点

智通财经
Aug 17
【阿斯利康终止一项肺癌三期临床试验,称疗效难达主要终点】8月17日,阿斯利康宣布终止eVOLVE-Lung02三期临床试验。该试验评估volrustomig联合化疗作为转移性非小细胞肺癌一线治疗的效果,与帕博利珠单抗联合化疗进行比较。独立数据监查委员会审查试验数据后认为,在PD-L1表达低于1%的患者中,该联合疗法不太可能达到无进展生存期和总生存期两项主要终点。阿斯利康表示,volrustomig联合化疗的安全性与已知药物特征一致,未发现新的安全性信号。公司将与研究人员合作,确保患者获得持续治疗和适当随访。其他volrustomig三期试验仍按计划推进。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10